News

Our Q2 2023 newsletter focusses on synthesis of acyl glucuronides, hydroxylated metabolites and our latest blogs

Hypha Discovery has a great opportunity for a lab-based chemist with purification experience to join our team in Oxfordshire. Join us and learn from the best!

Metabolites of the FDA approved anti-fungal drug rezafungin were made by Hypha’s microbial biotransformation system.

Our Q1 2023 newsletter focusses on Hypha’s recombinant enzymes, in particular innovations to the PolyCYPs platform.

Our Q4 2022 newsletter focusses on synthesis of deuterated metabolites with case studies to illustrate biotransformation and chemical routes.

Hypha’s Q3 2022 newsletter highlights our new gut metabolites service and a case study featuring the production of amino acid conjugates by microbial biotransformation.

Hypha’s Q2 2022 newsletter features synthesis of GSH conjugates using PolyCYPs enzymes, metabolite purification case studies, and information on our late-stage oxidation kits.

Hypha’s new service for accessing API degradation products and impurities is featured in our Q1 2022 newsletter. Also highlighted is the CYP active site engineering our Recombinant Technologies Team have undertaken to further develop PolyCYPs enzymes.

In our Q4 2021 technical newsletter we describe how Hypha used PolyCYPs to help the Open Source Antibiotics team identify a drug metabolite.

We look at the synthesis of glucuronides and glucose conjugates in our Q3 2021 technical newsletter.

We discuss the synthesis of deuterated metabolites and purification of metabolites from complex mixtures in our Q2 2021 newsletter.